Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SAGE | US
-0.34
-4.87%
Healthcare
Biotechnology
30/06/2024
04/10/2024
6.64
6.63
7.04
6.47
Sage Therapeutics Inc. a biopharmaceutical company develops and commercializes brain health medicines. Its product candidates include ZULRESSO a CIV injection for the treatment of postpartum depression (PPD) in adults; zuranolone a neuroactive steroid which has completed Phase III clinical trials for treating PPD and major depressive disorders as well as is in Phase II clinical trials for treatment resistant depression generalized anxiety disorders and bipolar depression; and SAGE-324 a compound that is in Phase II clinical trial to treat essential tremors as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases. Its product pipeline also comprises SAGE-689 that is in Phase II clinical trial for treating acute GABA hypofunction; SAGE-718 an oxysterol-based positive allosteric modulator of the NMDA receptor which is in Phase II clinical trial for the treatment of depression Huntington's disease Alzheimer's disease attention deficit hyperactivity disorder schizophrenia and neuropathic pain. Sage Therapeutics Inc. has a strategic collaboration with Shionogi & Co. Ltd. for the development and commercialization of zuranolone in Japan Taiwan and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma Inc. and changed its name to Sage Therapeutics Inc. in September 2011. Sage Therapeutics Inc. was incorporated in 2010 and is headquartered in Cambridge Massachusetts.
View LessLow Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
45.0%1 month
48.0%3 months
68.9%6 months
69.4%-
-
0.71
0.00
0.00
-0.33
2.10
0.74
-448.12M
405.37M
405.37M
-
-1.29K
-
249.80
-55.28
9.60
10.81
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
1.53
Range1M
1.66
Range3M
7.00
Rel. volume
1.34
Price X volume
5.76M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Xeris Pharmaceuticals Inc | XERS | Biotechnology | 2.98 | 444.02M | 2.41% | n/a | -1398.96% |
Absci Corporation Common Stock | ABSI | Biotechnology | 3.88 | 440.60M | 2.11% | n/a | 6.02% |
Foghorn Therapeutics Inc | FHTX | Biotechnology | 7.83 | 433.22M | -6.00% | n/a | -285.69% |
Esperion Therapeutics Inc | ESPR | Biotechnology | 2.16 | 423.85M | 18.68% | n/a | -161.71% |
Verve Therapeutics Inc. Common Stock | VERV | Biotechnology | 5 | 423.12M | 4.17% | n/a | 13.27% |
Taysha Gene Therapies Inc | TSHA | Biotechnology | 2.01 | 417.91M | -1.95% | n/a | 53.02% |
LRMR | LRMR | Biotechnology | 6.65 | 408.81M | 5.72% | n/a | 2.65% |
Theravance Biopharma Inc | TBPH | Biotechnology | 8.1 | 396.27M | -1.34% | n/a | 24.09% |
Voyager Therapeutics Inc | VYGR | Biotechnology | 7.04 | 383.91M | 20.96% | 21.67 | 13.99% |
Biomea Fusion Inc. Common Stock | BMEA | Biotechnology | 10.48 | 379.48M | 3.46% | n/a | 9.95% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Urban One Inc | UONEK | Broadcasting - Radio | 1.02 | 57.65M | -4.67% | n/a | 268.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.33 | 0.76 | Cheaper |
Ent. to Revenue | 2.10 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 0.71 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 68.93 | 74.67 | Par |
Debt to Equity | 0.00 | -1.82 | Expensive |
Debt to Assets | 0.00 | 0.26 | Cheaper |
Market Cap | 405.37M | 3.73B | Emerging |